Physician profile
Mark Zuckerman
NPI 1790846244
$13,662.96
in general payments reported to CMS, 2019-2025
53 companies · $2,263 in 2025
The $2,263 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,101 · 2020: $1,314 · 2021: $1,890 · 2022: $1,819 · 2023: $2,362 · 2024: $1,914 · 2025: $2,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,539.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,408.13 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Abbvie INC. | $1,035.06 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Lundbeck LLC | $871.22 | 2019-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $758.53 | 2019-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $675.95 | 2019-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $647.27 | 2019-2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $581.09 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Teva Pharmaceuticals USA, INC. | $570.16 | 2019-2024 | Austedo Xr |
| Ucb, INC. | $494.36 | 2019-2025 | Rystiggo, Briviact |
| Lilly USA, LLC | $491.96 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Otsuka America Pharmaceutical, INC. | $430.83 | 2023-2025 | Rexulti, Nuedexta |
| Pfizer INC. | $364.34 | 2023-2025 | |
| Kyowa Kirin, INC. | $338.69 | 2020-2024 | Nourianz |
| Argenx US, INC. | $287.59 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Eisai INC. | $280.02 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Zuckerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.